Search research articles
Contact Us
Filters
Showing results (81-90 of 93) with videos related to
Page
of 10
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2023
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis
Juergen Hench, Daniela Mihic-Probst, Abbas Agaimy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas
Philipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Journal for Immunotherapy of Cancer
|
April 7, 2023
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
Luiza Martins Nascentes Melo, Dayana Herrera-Rios, Daniel Hinze, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Frontiers in Immunology
|
August 18, 2018
The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris-Analysis of Four Different Ethnic Cohorts
Andreas Recke, Sarah Konitzer, Susanne Lemcke, et al.
Journal of Autoimmunity
|
July 29, 2021
Genetic association and differential expression of HLAComplexGroup lncRNAs in pemphigus
Amanda Salviano-Silva, Mareike Becker, Danillo G Augusto, et al.
Page
of 10
Search research articles
Search
Showing results (81-90 of 93) with videos related to
Sort By:
Page
of 10
European Journal of Cancer (Oxford, England : 1990)
|
December 22, 2021
TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy
Carl M Thielmann, Johanna Matull, Anne Zaremba, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 11, 2023
Characterisation and outcome of RAC1 mutated melanoma
Georg C Lodde, Philipp Jansen, Rudolf Herbst, et al.
Frontiers in Oncology
|
October 8, 2021
Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan-Malte Placke, Camille Soun, Jenny Bottek, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 25, 2023
Clinical, histopathological and molecular features of dedifferentiated melanomas: An EORTC Melanoma Group Retrospective Analysis
Juergen Hench, Daniela Mihic-Probst, Abbas Agaimy, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 17, 2024
Shortened progression free and overall survival to immune-checkpoint inhibitors in BRAF-, RAS- and NF1- ("Triple") wild type melanomas
Philipp Jansen, Wolfgang Galetzka, Georg C Lodde, et al.
Ebiomedicine
|
September 3, 2023
Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma - analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
Jan-Malte Placke, Mona Kimmig, Klaus Griewank, et al.
Journal for Immunotherapy of Cancer
|
April 7, 2023
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
Luiza Martins Nascentes Melo, Dayana Herrera-Rios, Daniel Hinze, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2021
NF1-mutated melanomas reveal distinct clinical characteristics depending on tumour origin and respond favourably to immune checkpoint inhibitors
Carl M Thielmann, Eleftheria Chorti, Johanna Matull, et al.
Frontiers in Immunology
|
August 18, 2018
The p.Arg435His Variation of IgG3 With High Affinity to FcRn Is Associated With Susceptibility for Pemphigus Vulgaris-Analysis of Four Different Ethnic Cohorts
Andreas Recke, Sarah Konitzer, Susanne Lemcke, et al.
Journal of Autoimmunity
|
July 29, 2021
Genetic association and differential expression of HLAComplexGroup lncRNAs in pemphigus
Amanda Salviano-Silva, Mareike Becker, Danillo G Augusto, et al.
Page
of 10